ClinicalTrials.gg
TerminatedNCT05932212Updated Sep 28, 2026

AK104 for Recurrent or Metastatic Vulvar Cancer

A Phase 2 interventional study of AK104 and AK104+ Paclitaxel+Cisplatin or Carboplatin in Vulvar Cancer, sponsored by Akeso. Terminated at 6 sites in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision
Updated Sep 28, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Vulvar Neoplasms with a site in China — 9 open to participants now, 12 under way, 3 of them phase 3. Vulvar Neoplasms · China.

Enrollment
15th of 19
20 · median 54
Started
2023
with 4 others
Phase 2
5 of 21
2 open now
Registered
14th of 21
by date
Lead sponsor
1 of 21
Akeso

Among the 21 studies in Vulvar Neoplasms with a site in China, this one is the 15th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2023, is one of 5 in phase 2, and was the 14th registered.

Vulvar Neoplasms

236 studies on the registry are indexed under Vulvar Neoplasms; 69 are open to participants now.

Browse Vulvar Neoplasms studies →

Open to participants now

9 of the 21 studies in Vulvar Neoplasms with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 53 Vulvar Neoplasms studies recruiting now, 39 (74%) set no upper age limit and 7 (13%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Vulvar Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.

03

Conditions studied

  • Vulvar Cancer

Browse trials for

Keywords

  • PD-1/CTLA-4
  • vulvar cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age >=18 and \<=80. of 0 or 2. ≥ 3 months. confirmed vulvar cancer (squamous cell carcinoma or adenosquamous carcinoma), not amenable to curative surgery or radical radiotherapy.

For Cohort A, subjects should have experienced failure on at least one previous systemic therapy, or intolerance to standard therapy.

At least one measurable tumor lesion per v1.1. Adequate organ function as assessed in the laboratory tests. Female subjects of must have a negative serum pregnancy test prior to the the first administration and agree to use effective methods of

Exclusion criteria

Exclusion Criteria:

Subjects with other histopathological types of vulvar cancer, such as melanoma, sarcoma, etc.

Systemic or curative (surgery or radiotherapy) anti-tumor therapy within 4 weeks prior to the first administration.

Previous treatment with (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.).

Active or potentially recurrent disease.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Cohort A: AK104

    AK104 monotherapy

    Drug: AK104

  • Experimental
    Cohort B: AK104+chemotherapy

    AK104 combined with platinum-based chemotherapy (paclitaxel+ cisplatin or carboplatin)

    Drug: AK104+ Paclitaxel+Cisplatin or Carboplatin

Interventions

  • DrugAK104

    AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.

    Also known as: Cadonilimab

  • DrugAK104+ Paclitaxel+Cisplatin or Carboplatin

    AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) assessed by investigator.

    The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1

    Time frame: Up to approximately 1 years

Secondary outcomes

  1. Progression-free survival (PFS) Assessed by investigator

    The time from the first administration to the first documented progressive disease (PD) or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  2. Duration of Response (DOR) Assessed by investigator

    Measured from the date of partial or complete response to therapy until the disease progression per RECIST v1.1 criteria

    Time frame: Up to approximately 2 years

  3. Disease control rate (DCR) Assessed by investigator

    The proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥6 weeks) based on RECIST

    Time frame: Up to approximately 1 years

  4. Time to Response (TTR) Assessed by investigator

    The time from the first administration to the date of documented CR or PR

    Time frame: Up to approximately 1 years

  5. Overall survival (OS)

    The time from the first administration to death due to any cause

    Time frame: Up to approximately 2 years

  6. Adverse Events (AEs)

    Characterization of incidence, severity and abnormal clinically significant manifestation or laboratory findings.

    Time frame: Up to approximately 2 years

  7. serum concentrations of AK104

    assessment of PK include serum concentrations of AK104 at different timepoints after study drug administration

    Time frame: Up to approximately 2 years

  8. Antidrug antibodies (ADA) of AK104

    Proportion of subjects who develop detectable anti-drug antibodies (ADAs)

    Time frame: Up to approximately 2 years

07

Study locations

6 sites
  • Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital
    Fuzhou, Fujian 350000, China
  • Sun Yant-Sen Memorial Hospital
    Guangzhou, Guangdong 510000, China
  • The Fourth Hospital of Hebei Medical University
    Shijiangzhuang, Hebei 050000, China
  • Liaoning Cancer Hospital & Insitut
    Shenyang, Liaoning 110042, China
  • Tianjin medical university Cancer Institut & Hospital
    Tianjin, Tianjin Municipality 300000, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2023 to primary completion in May 2026, 33 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Dec 2025 → May 2026 and completion Dec 2025 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 6, 2023
StartActual
Aug 25, 2023
Primary completionActual
May 31, 2026was Dec 2025
CompletionActual
May 31, 2026was Dec 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Sponsor decision
changed Sep 28, 2026
Sites
1 site added, 1 site removed
Show site
  • Tianjin medical university Cancer Institut & Hospital · Tianjin, China
Show 1 removed
  • Tianjin medical university Cancer Institut & Hospital · Tianjin, China
Sep 28, 2026
Primary completion
Dec 15, 2025→May 31, 2026 (actual)
Sep 28, 2026
Study completion
Dec 15, 2025→May 31, 2026 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Terminated
    Why stopped Sponsor decision
    1 site added, 1 site removed
    Show site
    • Tianjin medical university Cancer Institut & Hospital · Tianjin, China
    Show 1 removed
    • Tianjin medical university Cancer Institut & Hospital · Tianjin, China
    Primary completion Dec 15, 2025→May 31, 2026 (now actual)
    Study completion Dec 15, 2025→May 31, 2026 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05932212
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Aug 25, 2023
Primary completion
May 31, 2026
Completion
May 31, 2026
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion